Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:AFMD
- CUSIP: N/A
- Web: www.affimed.com
Capitalization:- Market Cap: $92.27 million
- Outstanding Shares: 43,938,000
Average Prices:- 50 Day Moving Avg: $2.09
- 200 Day Moving Avg: $2.24
- 52 Week Range: $1.65 - $3.19
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.00
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $3.99 million
- Price / Sales: 23.13
- Book Value: $1.10 per share
- Price / Book: 1.91
Profitability:- EBIDTA: ($36,260,000.00)
- Net Margins: -978.31%
- Return on Equity: -73.85%
- Return on Assets: -59.02%
Debt:- Debt-to-Equity Ratio: 0.13%
- Current Ratio: 6.69%
- Quick Ratio: 6.65%
Misc:- Average Volume: 244,594 shs.
- Beta: 3.61
- Short Ratio: 2.6
Frequently Asked Questions for Affimed N.V. (NASDAQ:AFMD)
What is Affimed N.V.'s stock symbol?
Affimed N.V. trades on the NASDAQ under the ticker symbol "AFMD."
How were Affimed N.V.'s earnings last quarter?
Affimed N.V. (NASDAQ:AFMD) announced its earnings results on Thursday, August, 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.22) by $0.02. The firm had revenue of $0.51 million for the quarter, compared to analyst estimates of $1.31 million. Affimed N.V. had a negative net margin of 978.31% and a negative return on equity of 73.85%. Affimed N.V.'s revenue was down 75.4% compared to the same quarter last year. During the same quarter last year, the business earned ($0.24) earnings per share. View Affimed N.V.'s Earnings History.
When will Affimed N.V. make its next earnings announcement?
Where is Affimed N.V.'s stock going? Where will Affimed N.V.'s stock price be in 2017?
4 equities research analysts have issued twelve-month target prices for Affimed N.V.'s shares. Their forecasts range from $2.00 to $10.00. On average, they anticipate Affimed N.V.'s stock price to reach $5.38 in the next twelve months. View Analyst Ratings for Affimed N.V..
Who are some of Affimed N.V.'s key competitors?
Some companies that are related to Affimed N.V. include Verastem (VSTM), Threshold Pharmaceuticals (MTEM), Fate Therapeutics (FATE), Vascular Biogenics (VBLT), Cempra (CEMP), Recro Pharma (REPH), Conatus Pharmaceuticals (CNAT), Summit Therapeutics PLC (SMMT), ProQR Therapeutics N.V. (PRQR), Redhill Biopharma (RDHL), Synthetic Biologics (SYN), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Cellular Biomedicine Group (CBMG), Dimension Therapeutics (DMTX), XBiotech (XBIT), Adverum Biotechnologies (ADVM) and Trevena (TRVN).
Who owns Affimed N.V. stock?
Affimed N.V.'s stock is owned by a variety of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (8.85%), Bain Capital Public Equity Management LLC (7.30%), Tekla Capital Management LLC (3.20%), Nationwide Fund Advisors (1.15%), California Public Employees Retirement System (0.40%) and DAFNA Capital Management LLC (0.21%). View Institutional Ownership Trends for Affimed N.V..
Who bought Affimed N.V. stock? Who is buying Affimed N.V. stock?
How do I buy Affimed N.V. stock?
Shares of Affimed N.V. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Affimed N.V.'s stock price today?
One share of Affimed N.V. stock can currently be purchased for approximately $2.10.
MarketBeat Community Rating for Affimed N.V. (NASDAQ AFMD)MarketBeat's community ratings are surveys of what our community members think about Affimed N.V. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Affimed N.V. (NASDAQ:AFMD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $5.38 (155.95% upside) |
Analysts' Ratings History for Affimed N.V. (NASDAQ:AFMD)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/27/2017 | Jefferies Group LLC | Reiterated Rating | Hold | $2.50 | Low |  |
| 7/13/2017 | SunTrust Banks, Inc. | Initiated Coverage | Buy -> Buy | $7.00 | High | |
| 5/18/2017 | Oppenheimer Holdings, Inc. | Set Price Target | Buy | $10.00 | Low | |
| 11/3/2016 | Leerink Swann | Reiterated Rating | Hold | $2.00 | N/A | |
| 5/18/2016 | Wells Fargo & Company | Reiterated Rating | Buy | | N/A | |
| 4/11/2016 | BMO Capital Markets | Initiated Coverage | Outperform | $7.00 | N/A | |
| 12/10/2015 | Laidlaw | Initiated Coverage | Buy | $15.00 | N/A | |
(Data available from 9/24/2015 forward)
Earnings History for Affimed N.V. (NASDAQ:AFMD)Earnings History by Quarter for Affimed N.V. (NASDAQ AFMD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/1/2017 | | | | | | | | |
| 8/3/2017 | 6/30/2017 | ($0.22) | ($0.20) | $1.31 million | $0.51 million | View | Listen | |
| 5/17/2017 | 3/31/2017 | ($0.24) | ($0.21) | $1.73 million | $1.94 million | View | N/A | |
| 3/30/2017 | 12/31/2016 | ($0.31) | ($0.17) | $1.20 million | $1.37 million | View | N/A | |
| 11/2/2016 | Q316 | ($0.26) | ($0.31) | $2.65 million | $0.94 million | View | N/A | |
| 8/10/2016 | Q216 | ($0.22) | ($0.24) | $2.10 million | $2.07 million | View | Listen | |
| 5/18/2016 | Q116 | ($0.15) | ($0.25) | $1.88 million | $1.90 million | View | Listen | |
| 3/30/2016 | Q415 | ($0.18) | ($0.19) | $1.71 million | $1.66 million | View | Listen | |
| 11/10/2015 | Q315 | ($0.25) | ($0.27) | $1.87 million | $1.20 million | View | Listen | |
| 8/4/2015 | Q215 | ($0.14) | ($0.21) | $2.56 million | $2.21 million | View | N/A | |
| 5/21/2015 | Q115 | ($0.14) | ($0.07) | $4.75 million | $2.82 million | View | Listen | |
| 3/25/2015 | Q414 | ($0.39) | ($0.24) | $0.89 million | $0.09 million | View | N/A | |
| 11/18/2014 | Q314 | ($0.33) | $2.69 | $0.89 million | $2.35 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Affimed N.V. (NASDAQ:AFMD)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q2 2017 | 2 | ($0.21) | ($0.18) | ($0.20) |
| Q3 2017 | 4 | ($0.22) | ($0.19) | ($0.20) |
| Q4 2017 | 3 | ($0.24) | ($0.18) | ($0.21) |
(Data provided by Zacks Investment Research)
Dividend History for Affimed N.V. (NASDAQ:AFMD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Affimed N.V. (NASDAQ:AFMD)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Affimed N.V. (NASDAQ:AFMD)
Latest Headlines for Affimed N.V. (NASDAQ:AFMD)
| Source: |
|
| Date | Headline |
|---|
 | Affimed to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
finance.yahoo.com - September 22 at 2:57 PM |
 | Affimed (AFMD) Names Dr. Wolfgang Fischer as Chief Operating Officer
www.streetinsider.com - September 13 at 4:29 PM |
 | New operating chief at Affimed
seekingalpha.com - September 13 at 4:29 PM |
| What Is Affimed NV’s (AFMD) Share Price Doing?
finance.yahoo.com - September 13 at 4:29 PM |
 | Affimed Appoints Dr. Wolfgang Fischer as Chief Operating Officer
feeds.benzinga.com - September 13 at 5:56 AM |
 | Affimed N.V. (AFMD) Expected to Post Quarterly Sales of $970,000.00
www.americanbankingnews.com - September 12 at 9:18 AM |
| Affimed N.V. (AFMD) Presents At 2017 Wells Fargo Healthcare Conference - Slideshow
seekingalpha.com - September 8 at 3:56 PM |
| Affimed NV :AFMD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 6, 2017
finance.yahoo.com - September 6 at 3:31 PM |
| ValuEngine Lowers Affimed N.V. (AFMD) to Strong Sell
www.americanbankingnews.com - September 3 at 11:22 PM |
| Affimed N.V. (AFMD) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 1 at 2:44 AM |
| Analysts Expect Affimed N.V. (AFMD) Will Post Quarterly Sales of $970,000.00
www.americanbankingnews.com - August 24 at 2:56 AM |
| Affimed N.V. (NASDAQ:AFMD) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 7 at 8:06 AM |
| Brokerages Expect Affimed N.V. (AFMD) Will Announce Quarterly Sales of $970,000.00
www.americanbankingnews.com - August 6 at 7:12 AM |
| -$0.21 Earnings Per Share Expected for Affimed N.V. (NASDAQ:AFMD) This Quarter
www.americanbankingnews.com - August 4 at 2:26 PM |
| FY2017 Earnings Forecast for Affimed N.V. Issued By Jefferies Group (AFMD)
www.americanbankingnews.com - August 4 at 11:54 AM |
| Oppenheimer Holdings Comments on Affimed N.V.'s Q3 2017 Earnings (AFMD)
www.americanbankingnews.com - August 4 at 8:48 AM |
| Affimed N.V. (NASDAQ:AFMD) to Post Q3 2017 Earnings of ($0.20) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - August 4 at 8:48 AM |
| Q3 2017 Earnings Forecast for Affimed N.V. Issued By SunTrust Banks (AFMD)
www.americanbankingnews.com - August 3 at 8:48 AM |
| Affimed N.V. (AFMD) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - August 2 at 2:24 PM |
| Edited Transcript of AFMD earnings conference call or presentation 1-Aug-17 12:30pm GMT
finance.yahoo.com - August 2 at 2:40 AM |
| Affimed Reports Financial Results for Second Quarter 2017
finance.yahoo.com - August 1 at 4:36 PM |
| Affimed N.V. (AFMD) Earns "Hold" Rating from Jefferies Group LLC
www.americanbankingnews.com - July 27 at 6:50 PM |
| Affimed N.V. (NASDAQ:AFMD) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - July 27 at 7:02 AM |
| SunTrust Banks, Inc. Initiates Coverage on Affimed N.V. (NASDAQ:AFMD)
www.americanbankingnews.com - July 16 at 5:14 PM |
| $1.42 Million in Sales Expected for Affimed N.V. (AFMD) This Quarter
www.americanbankingnews.com - July 15 at 9:20 AM |
| Affimed N.V. (AFMD) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - July 13 at 10:23 PM |
| -$0.22 Earnings Per Share Expected for Affimed N.V. (AFMD) This Quarter
www.americanbankingnews.com - July 13 at 8:28 AM |
| Affimed (AFMD) Looks Good: Stock Moves Up 8.7% in Session
finance.yahoo.com - July 10 at 3:16 PM |
| Affimed N.V. (NASDAQ:AFMD) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - July 1 at 10:04 AM |
| Affimed Presents Preclinical Data on AFM24 and AFM26 at EACR-AACR-SIC 2017
feeds.benzinga.com - June 27 at 6:28 AM |
| Zacks: Analysts Expect Affimed N.V. (AFMD) Will Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - June 19 at 8:16 AM |
| Affimed Presents Data on First-in-Class BCMA-Targeting Immune Cell Engager AFM26 at ASCO Annual Meeting 2017
finance.yahoo.com - June 6 at 9:46 AM |
| Research Analysts Offer Predictions for Affimed NV's Q2 2017 Earnings (AFMD)
www.americanbankingnews.com - May 22 at 7:18 AM |
| Q2 2017 EPS Estimates for Affimed NV (AFMD) Lowered by Leerink Swann
www.americanbankingnews.com - May 22 at 7:18 AM |
| Q3 2017 EPS Estimates for Affimed NV (AFMD) Reduced by Analyst
www.americanbankingnews.com - May 22 at 7:18 AM |
| Oppenheimer Holdings Inc. Analysts Give Affimed NV (AFMD) a $10.00 Price Target
www.americanbankingnews.com - May 19 at 5:54 PM |
| Affimed NV (AFMD) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - May 19 at 12:50 AM |
| Affimed to Present Immune Cell Engager Data at ASCO Annual Meeting and EACR-AACR-SIC Special Conference
finance.yahoo.com - May 17 at 8:26 PM |
| Affimed Announces First Quarter 2017 Financial Results and Corporate Update Conference Call
finance.yahoo.com - May 10 at 9:28 AM |
| Affimed NV (AFMD) Earns Coverage Optimism Rating of 0.23
www.americanbankingnews.com - May 4 at 7:54 AM |
| Affimed NV (AFMD) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 4 at 1:04 AM |
| Affimed NV (AFMD) Expected to Announce Quarterly Sales of $1.79 Million
www.americanbankingnews.com - May 3 at 4:38 PM |
| Affimed NV (AFMD) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 3 at 12:22 AM |
| Affimed NV (AFMD) Getting Somewhat Favorable Media Coverage, Study Shows
www.americanbankingnews.com - May 1 at 11:41 AM |
| Affimed NV (AFMD) Expected to Announce Earnings of -$0.27 Per Share
www.americanbankingnews.com - May 1 at 10:06 AM |
| Affimed NV (AFMD) Earning Somewhat Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - April 27 at 9:34 AM |
| Affimed NV (AFMD) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - April 26 at 6:46 PM |
| Affimed NV (AFMD) Receives Media Impact Rating of 0.56
www.americanbankingnews.com - April 24 at 12:10 PM |
| Zacks Investment Research Lowers Affimed NV (AFMD) to Hold
www.americanbankingnews.com - April 21 at 9:46 PM |
| Affimed NV (AFMD) Earns Media Impact Score of 0.40
www.americanbankingnews.com - April 20 at 10:45 AM |
Affimed N.V. (AFMD) Chart for Sunday, September, 24, 2017
